90 related articles for article (PubMed ID: 38164884)
21. An Improved CRISPR/dCas9 Interference Tool for Neuronal Gene Suppression.
Duke CG; Bach SV; Revanna JS; Sultan FA; Southern NT; Davis MN; Carullo NVN; Bauman AJ; Phillips RA; Day JJ
Front Genome Ed; 2020; 2():9. PubMed ID: 34713218
[TBL] [Abstract][Full Text] [Related]
22. Rapid generation of CRISPR/dCas9-regulated, orthogonally repressible hybrid T7-lac promoters for modular, tuneable control of metabolic pathway fluxes in Escherichia coli.
Cress BF; Jones JA; Kim DC; Leitz QD; Englaender JA; Collins SM; Linhardt RJ; Koffas MA
Nucleic Acids Res; 2016 May; 44(9):4472-85. PubMed ID: 27079979
[TBL] [Abstract][Full Text] [Related]
23. Quantitative and modularized CRISPR/dCas9-dCpf1 dual function system in
Feng Q; Ning X; Qin L; Li J; Li C
Front Bioeng Biotechnol; 2023; 11():1218832. PubMed ID: 38026848
[No Abstract] [Full Text] [Related]
24. CRISPR/dCas9-Mediated Multiplex Gene Repression in Streptomyces.
Zhao Y; Li L; Zheng G; Jiang W; Deng Z; Wang Z; Lu Y
Biotechnol J; 2018 Sep; 13(9):e1800121. PubMed ID: 29862648
[TBL] [Abstract][Full Text] [Related]
25. Integration and exchange of split dCas9 domains for transcriptional controls in mammalian cells.
Ma D; Peng S; Xie Z
Nat Commun; 2016 Oct; 7():13056. PubMed ID: 27694915
[TBL] [Abstract][Full Text] [Related]
26. A versatile toolbox for CRISPR-based genome engineering in Pichia pastoris.
Liao X; Li L; Jameel A; Xing XH; Zhang C
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9211-9218. PubMed ID: 34773154
[TBL] [Abstract][Full Text] [Related]
27. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
28. CRISPR-Act2.0: An Improved Multiplexed System for Plant Transcriptional Activation.
Malzahn A; Zhang Y; Qi Y
Methods Mol Biol; 2019; 1917():83-93. PubMed ID: 30610630
[TBL] [Abstract][Full Text] [Related]
29. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.
Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P
Oncotarget; 2016 Sep; 7(37):60535-60554. PubMed ID: 27528034
[TBL] [Abstract][Full Text] [Related]
30. Programmable Transcriptional Modulation with a Structured RNA-Mediated CRISPR-dCas9 Complex.
He M; Zhou X; Li Z; Yin X; Han W; Zhou J; Sun X; Liu X; Yao D; Liang H
J Am Chem Soc; 2022 Jul; 144(28):12690-12697. PubMed ID: 35792375
[TBL] [Abstract][Full Text] [Related]
31. Positional effects on efficiency of CRISPR/Cas9-based transcriptional activation in rice plants.
Gong X; Zhang T; Xing J; Wang R; Zhao Y
aBIOTECH; 2020 Jan; 1(1):1-5. PubMed ID: 36305003
[TBL] [Abstract][Full Text] [Related]
32. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers.
Gao X; Tsang JC; Gaba F; Wu D; Lu L; Liu P
Nucleic Acids Res; 2014 Nov; 42(20):e155. PubMed ID: 25223790
[TBL] [Abstract][Full Text] [Related]
33. Orthogonal control of gene expression in plants using synthetic promoters and CRISPR-based transcription factors.
Kar S; Bordiya Y; Rodriguez N; Kim J; Gardner EC; Gollihar JD; Sung S; Ellington AD
Plant Methods; 2022 Mar; 18(1):42. PubMed ID: 35351174
[TBL] [Abstract][Full Text] [Related]
34. Synthetic far-red light-mediated CRISPR-dCas9 device for inducing functional neuronal differentiation.
Shao J; Wang M; Yu G; Zhu S; Yu Y; Heng BC; Wu J; Ye H
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6722-E6730. PubMed ID: 29967137
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges.
Luo N; Zhong W; Li J; Lu J; Dong R
Mol Biol Rep; 2022 Dec; 49(12):11403-11408. PubMed ID: 35960410
[TBL] [Abstract][Full Text] [Related]
36. Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Baeumler TA; Ahmed AA; Fulga TA
Cell Rep; 2017 Sep; 20(11):2639-2653. PubMed ID: 28903044
[TBL] [Abstract][Full Text] [Related]
37. Applications of Engineered DNA-Binding Molecules Such as TAL Proteins and the CRISPR/Cas System in Biology Research.
Fujita T; Fujii H
Int J Mol Sci; 2015 Sep; 16(10):23143-64. PubMed ID: 26404236
[TBL] [Abstract][Full Text] [Related]
38. Modularized CRISPR/dCas9 effector toolkit for target-specific gene regulation.
Agne M; Blank I; Emhardt AJ; Gäbelein CG; Gawlas F; Gillich N; Gonschorek P; Juretschke TJ; Krämer SD; Louis N; Müller A; Rudorf A; Schäfer LM; Scheidmann MC; Schmunk LJ; Schwenk PM; Stammnitz MR; Warmer PM; Weber W; Fischer A; Kaufmann B; Wagner HJ; Radziwill G
ACS Synth Biol; 2014 Dec; 3(12):986-9. PubMed ID: 25524106
[TBL] [Abstract][Full Text] [Related]
39. A Light-Inducible Split-dCas9 System for Inhibiting the Progression of Bladder Cancer Cells by Activating p53 and E-cadherin.
Huang X; Zhou Q; Wang M; Cao C; Ma Q; Ye J; Gui Y
Front Mol Biosci; 2020; 7():627848. PubMed ID: 33469550
[TBL] [Abstract][Full Text] [Related]
40. Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic
Himeda CL; Jones TI; Jones PL
Mol Ther Methods Clin Dev; 2021 Mar; 20():298-311. PubMed ID: 33511244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
